JP5203956B2 - メタロプロテイナーゼの調節のためのスルホンアミド誘導体とその使用 - Google Patents
メタロプロテイナーゼの調節のためのスルホンアミド誘導体とその使用 Download PDFInfo
- Publication number
- JP5203956B2 JP5203956B2 JP2008537083A JP2008537083A JP5203956B2 JP 5203956 B2 JP5203956 B2 JP 5203956B2 JP 2008537083 A JP2008537083 A JP 2008537083A JP 2008537083 A JP2008537083 A JP 2008537083A JP 5203956 B2 JP5203956 B2 JP 5203956B2
- Authority
- JP
- Japan
- Prior art keywords
- dihydroisoquinolin
- sulfonyl
- hydroxyformamide
- ethyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC1C(*)(*)*C(*)(*)c2c(*)c(C)c(C)c(*)c2C1(C)* Chemical compound CC1C(*)(*)*C(*)(*)c2c(*)c(C)c(C)c(*)c2C1(C)* 0.000 description 9
- VHXPKZQWUWXJAP-UHFFFAOYSA-N CC(C)(C)C(CS(N(CC1)Cc2c1ccc(Cl)c2)(=O)=O)N(C=O)O Chemical compound CC(C)(C)C(CS(N(CC1)Cc2c1ccc(Cl)c2)(=O)=O)N(C=O)O VHXPKZQWUWXJAP-UHFFFAOYSA-N 0.000 description 1
- VSOUJKWGYDTUDL-UHFFFAOYSA-N CCCCCC(CS(N1Cc2ccccc2CC1)(=O)=O)N(C=O)O Chemical compound CCCCCC(CS(N1Cc2ccccc2CC1)(=O)=O)N(C=O)O VSOUJKWGYDTUDL-UHFFFAOYSA-N 0.000 description 1
- KGUFTMIFHYCGMN-UHFFFAOYSA-N CS(N(CC1)Cc2c1ccc(Cl)c2)(=O)=O Chemical compound CS(N(CC1)Cc2c1ccc(Cl)c2)(=O)=O KGUFTMIFHYCGMN-UHFFFAOYSA-N 0.000 description 1
- FRAQVJJXBSUXEL-UHFFFAOYSA-N OCCC(CS(N(CC1)Cc2c1ccc(Cl)c2)(=O)=O)N(C=O)O Chemical compound OCCC(CS(N(CC1)Cc2c1ccc(Cl)c2)(=O)=O)N(C=O)O FRAQVJJXBSUXEL-UHFFFAOYSA-N 0.000 description 1
- MJVPIJSADMKNKT-UHFFFAOYSA-N ON(C(CS(N(CC1)CC(C2)=C1C=CC2F)(=O)=O)C1CCN(CCc2ccccc2)CC1)C=O Chemical compound ON(C(CS(N(CC1)CC(C2)=C1C=CC2F)(=O)=O)C1CCN(CCc2ccccc2)CC1)C=O MJVPIJSADMKNKT-UHFFFAOYSA-N 0.000 description 1
- WWMXPWXUCFALMR-UHFFFAOYSA-N ON(C(CS(N1Cc2ccccc2CC1)(=O)=O)c1cncnc1)C=O Chemical compound ON(C(CS(N1Cc2ccccc2CC1)(=O)=O)c1cncnc1)C=O WWMXPWXUCFALMR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73040405P | 2005-10-26 | 2005-10-26 | |
US60/730,404 | 2005-10-26 | ||
EP05110035 | 2005-10-26 | ||
EP05110035.2 | 2005-10-26 | ||
PCT/EP2006/067713 WO2007048788A1 (en) | 2005-10-26 | 2006-10-24 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009513601A JP2009513601A (ja) | 2009-04-02 |
JP5203956B2 true JP5203956B2 (ja) | 2013-06-05 |
Family
ID=35695473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008537083A Expired - Fee Related JP5203956B2 (ja) | 2005-10-26 | 2006-10-24 | メタロプロテイナーゼの調節のためのスルホンアミド誘導体とその使用 |
Country Status (22)
Country | Link |
---|---|
US (1) | US7879876B2 (da) |
EP (1) | EP1951674B1 (da) |
JP (1) | JP5203956B2 (da) |
KR (1) | KR20080064880A (da) |
CN (1) | CN101346353B (da) |
AT (1) | ATE534630T1 (da) |
AU (1) | AU2006307939B2 (da) |
BR (1) | BRPI0617931A2 (da) |
CA (1) | CA2623879C (da) |
CY (1) | CY1112370T1 (da) |
DK (1) | DK1951674T3 (da) |
EA (1) | EA013907B1 (da) |
ES (1) | ES2372866T3 (da) |
HK (1) | HK1123304A1 (da) |
HR (1) | HRP20110874T1 (da) |
IL (1) | IL190835A (da) |
PL (1) | PL1951674T3 (da) |
PT (1) | PT1951674E (da) |
RS (1) | RS52229B (da) |
SI (1) | SI1951674T1 (da) |
WO (1) | WO2007048788A1 (da) |
ZA (1) | ZA200803327B (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101389246B1 (ko) | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
RU2015111229A (ru) * | 2008-11-11 | 2015-11-20 | Новартис Аг | Кристаллические формы гидрохлорида финголимода |
SG175420A1 (en) | 2009-05-12 | 2011-12-29 | Albany Molecular Res Inc | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用 |
WO2010132437A1 (en) | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
HUE026406T2 (en) * | 2009-06-19 | 2016-06-28 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
KR20120045032A (ko) * | 2009-07-30 | 2012-05-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 크론병의 치료 |
HUE029983T2 (en) | 2009-08-10 | 2017-04-28 | Teva Pharma | Treatment of BDNF-related diseases with laquinimod |
EA201290837A1 (ru) * | 2010-03-03 | 2013-05-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение волчаночного нефрита с применением лаквинимода |
PT2542079E (pt) * | 2010-03-03 | 2014-07-18 | Teva Pharma | Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato |
WO2011109536A1 (en) * | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus arthritis using laquinimod |
JP5950428B2 (ja) * | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
CA2811504C (en) * | 2010-09-17 | 2018-06-05 | Kaken Pharmaceutical Co., Ltd. | Composition for maintaining function of platelets |
KR20140101333A (ko) | 2011-10-12 | 2014-08-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 및 핑골리모드의 조합을 이용한 다발성 경화증의 치료 |
AU2012337691B2 (en) * | 2011-11-18 | 2017-10-12 | Nitto Denko Corporation | Intestinal fibrosis treatment agent |
TW201345527A (zh) | 2012-02-03 | 2013-11-16 | Teva Pharma | 拉喹莫德於治療對第一線抗-TNFα療法無效之克隆氏症患者之用途 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
CN103102304B (zh) * | 2013-01-19 | 2015-03-11 | 安徽师范大学 | N-磺酰基取代四氢异喹啉衍生物的制备方法 |
WO2023147063A2 (en) * | 2022-01-28 | 2023-08-03 | Opna Bio SA | Compounds and methods for yap/tead modulation and indications therefor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
ATE356114T1 (de) * | 1999-06-04 | 2007-03-15 | Astrazeneca Ab | Inhibitoren von metalloproteinasen |
WO2001087844A1 (en) * | 2000-05-15 | 2001-11-22 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
GB0216383D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
SE0301922D0 (sv) * | 2003-06-27 | 2003-06-27 | Astrazeneca Ab | Novel compounds |
-
2006
- 2006-10-24 CN CN2006800490790A patent/CN101346353B/zh not_active Expired - Fee Related
- 2006-10-24 EA EA200801183A patent/EA013907B1/ru not_active IP Right Cessation
- 2006-10-24 KR KR1020087012135A patent/KR20080064880A/ko not_active Application Discontinuation
- 2006-10-24 AU AU2006307939A patent/AU2006307939B2/en not_active Ceased
- 2006-10-24 DK DK06807508.4T patent/DK1951674T3/da active
- 2006-10-24 CA CA2623879A patent/CA2623879C/en not_active Expired - Fee Related
- 2006-10-24 PT PT06807508T patent/PT1951674E/pt unknown
- 2006-10-24 SI SI200631208T patent/SI1951674T1/sl unknown
- 2006-10-24 RS RS20120059A patent/RS52229B/en unknown
- 2006-10-24 BR BRPI0617931-2A patent/BRPI0617931A2/pt not_active IP Right Cessation
- 2006-10-24 ZA ZA200803327A patent/ZA200803327B/xx unknown
- 2006-10-24 JP JP2008537083A patent/JP5203956B2/ja not_active Expired - Fee Related
- 2006-10-24 ES ES06807508T patent/ES2372866T3/es active Active
- 2006-10-24 PL PL06807508T patent/PL1951674T3/pl unknown
- 2006-10-24 AT AT06807508T patent/ATE534630T1/de active
- 2006-10-24 WO PCT/EP2006/067713 patent/WO2007048788A1/en active Application Filing
- 2006-10-24 EP EP06807508A patent/EP1951674B1/en active Active
- 2006-10-24 US US12/091,582 patent/US7879876B2/en not_active Expired - Fee Related
-
2008
- 2008-04-14 IL IL190835A patent/IL190835A/en not_active IP Right Cessation
-
2009
- 2009-04-06 HK HK09103218.1A patent/HK1123304A1/xx not_active IP Right Cessation
-
2011
- 2011-11-23 HR HR20110874T patent/HRP20110874T1/hr unknown
-
2012
- 2012-02-17 CY CY20121100170T patent/CY1112370T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN101346353A (zh) | 2009-01-14 |
AU2006307939B2 (en) | 2012-03-29 |
HRP20110874T1 (hr) | 2011-12-31 |
CY1112370T1 (el) | 2015-12-09 |
EP1951674B1 (en) | 2011-11-23 |
DK1951674T3 (da) | 2012-01-02 |
US20090221575A1 (en) | 2009-09-03 |
ES2372866T3 (es) | 2012-01-27 |
KR20080064880A (ko) | 2008-07-09 |
EP1951674A1 (en) | 2008-08-06 |
AU2006307939A1 (en) | 2007-05-03 |
IL190835A (en) | 2013-01-31 |
RS52229B (en) | 2012-10-31 |
SI1951674T1 (sl) | 2012-01-31 |
ZA200803327B (en) | 2009-09-30 |
PL1951674T3 (pl) | 2012-04-30 |
BRPI0617931A2 (pt) | 2011-08-09 |
WO2007048788A1 (en) | 2007-05-03 |
CN101346353B (zh) | 2012-01-11 |
CA2623879C (en) | 2014-03-25 |
ATE534630T1 (de) | 2011-12-15 |
PT1951674E (pt) | 2011-12-19 |
CA2623879A1 (en) | 2007-05-03 |
EA013907B1 (ru) | 2010-08-30 |
IL190835A0 (en) | 2008-11-03 |
EA200801183A1 (ru) | 2008-10-30 |
US7879876B2 (en) | 2011-02-01 |
JP2009513601A (ja) | 2009-04-02 |
HK1123304A1 (en) | 2009-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5203956B2 (ja) | メタロプロテイナーゼの調節のためのスルホンアミド誘導体とその使用 | |
CN113365988B (zh) | Shp2抑制剂及其应用 | |
EP1973900B1 (en) | Hydantoin compounds for the treatment of inflammatory disorders | |
JP4351053B2 (ja) | ジヒドロキシピリミジンカルボキサミド系hivインテグラーゼ阻害薬 | |
JP4854943B2 (ja) | ジペプチジルペプチダーゼ阻害剤 | |
CN1989106A (zh) | N-羟基酰胺衍生物及其应用 | |
US7102008B2 (en) | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | |
CN100439351C (zh) | 苯并呋喃衍生物 | |
JP2007530516A (ja) | 抗ウイルス剤として有用な4−カルボキシピラゾール誘導体 | |
JP2001518090A (ja) | 腫瘍壊死因子の阻害に有用な複素環により置換したヒドロキサム酸 | |
JP6441830B2 (ja) | カテプシンcの置換2−アザ−ビシクロ[2.2.1]ヘプタン−3−カルボン酸(シアノ−メチル)−アミド阻害剤 | |
CN101124213A (zh) | 磺酰氨基环状衍生物及其应用 | |
WO1998058930A1 (fr) | Composes de triazolo-1,4-diazepine et composition medicinale les contenant | |
JP5199109B2 (ja) | N−ヒドロキシアミド誘導体およびその使用 | |
JP2005501087A (ja) | アリールピペラジンとアリールピペリジン、およびメタロプロテイナーゼ阻害剤としてのそれらの使用 | |
US11673884B2 (en) | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | |
WO2023143401A1 (zh) | 作为masp-2抑制剂的化合物、药物组合物及其制备方法和用途 | |
KR101220615B1 (ko) | N-히드록시아미드 유도체 및 그의 용도 | |
JP2008531503A (ja) | グルココルチコイド受容体のモジュレーターとしてのナフタレン誘導体 | |
UA81271C2 (en) | 2-pyridone derivatives as inhibitors of neutrophile elastase, process for the preparation thereof and pharmaceutical composition based thereon | |
KR20070095950A (ko) | 술포닐 아미노 시클릭 유도체 및 그것의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091023 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120522 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120522 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120918 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121212 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130115 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130214 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5203956 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160222 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |